Magnetic pulse relief for migraines
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A hand-held device that fires a magnetic pulse to the back of the head may offer new hope to migraine sufferers, research suggests.
In tests, the machine, a single-pulse transcranial magnetic stimulation (sTMS), delivered pain relief for up to 48 hours with no noticeable side effects.
It was used on patients with "aura" – neurological effects that precede the headache, such as lights or lines in front of the eyes, visual "blank spots", and tingling or numbness. It affects about 20 per cent to 30 per cent of patients.
A group of 201 patients were randomly assigned either to receive treatment or a "sham" machine that produced no magnetic pulse.
They applyied two pulses 30 seconds apart as soon as possible after the onset of aura symptoms.
Of the 164 patients who treated at least one attack, 39 per cent from the sTMS group were pain free after two hours compared with 22 per cent of the "sham" group. Patients rated the device an average eight out of 10 for "user friendliness".
TMS works by changing the pattern of firing of neurons in the brain. Since its discovery in 1985, it has been used for anatomic brain mapping and diagnostic and therapeutic purposes.
Findings from the new study, led by Dr Richard Lipton, from the Albert Einstein College of Medicine in New York, are reported in the journal the Lancet Neurology.
The researchers wrote it could be "a promising acute treatment".
Migraine is often treated with drugs called triptans, but these are not effective or approved during the aura phase of an attack.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments